Effects Of Levosimendan On Right Heart Function

The right ventricular myocardium is weaker than the left,and its contraction is far less than that of the left ventricle.Its role and status as a blood pumping organ is weakened.Most of the current research focuses on the left ventricle,and drugs for treating patients with left heart failure cannot confirm the efficacy in the patients with right ventricular dysfunction.The prevalence of right heart failure cannot be underestimated.Related studies have shown that patients with left heart failure and pulmonary hypertension,if right heart failure complicated,would face increased mortality rate.Pulmonary hypertension caused by various causes continues to affect the right ventricular cardiomyocytes,leading to adaptive and damaging changes in myocardial cells and intercellular matrix,which promotes the occurrence of right heart failure.Levosimendan is a calcium ion sensitizer.It can relax vascular smooth muscle,protect the heart muscle,and increase myocardial contractility through its unique pharmacological pathway.It can improve the clinical symptoms of patients with heart failure while reducing pulmonary hypertension.Theoretically,prospects of levosimendan maybe limitedby lack of high-quality clinical research.To evaluate the effects on right heart function of Levosimendan and provide evidence-based evidence for rational drug use by meta-analysis,we searched for the literature on the Chinese and English databases of Pubmed,Web of Science,Embase,Cochrane Library,CNKI,CBM,Weipu,and Wanfang.Then the literature was obtained according to the established inclusion and exclusion criteria.The quality of the literature was evaluated and comprehensive data analysis was performed using RevMan5.3 software.The results: FAC value to evaluate heart function including 119 patients,with values of MD(mean difference)of 3.01 95%CI(0.68,5.33)%,P<0.05.Tei value assessed cardiac function in 126 patients,with a MD of-0.2095%CI(-0.22,-0.18),P< 0.05.The TAPSE value was used as a evaluation parameter in 94 patients,with a MD of 1.53 95%CI(0.53,2.53),P < 0.05.There were 371 patients who used SPAP as the evaluation parameter with values of MD(mean difference)of-5.2295%CI(-7.23,-3.21),P<0.05.There were 371 patients who used SPAP as the evaluation parameter,with values of MD(mean difference)of-5.22 95%CI(-7.23,-3.21),P<0.05.There were 371 patients who used SPAP as the evaluation parameter with values of MD(mean difference)of-5.22 95%CI(-7.23,-3.21),P<0.05.There were 83 patients who used mPAP as the evaluation parameter,with values of MD(mean difference)of-8.29 95%CI(-16.08,-0.51),P<0.05.There were 44 patients whoused PVR as the evaluation parameter,with values of MD(mean difference)of-39.84 95%CI(-67.75,-11.93),P<0.05.Conclusions:Levosimendan can effectively improve right ventricular function and reduce the level of pulmonary artery press.